Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results

Table 6 Univariable and multivariable logistic regression analysis of factors associated with SVR12 for 215 patients treated with sofosbuvir/ribavirin and a confirmed outcome

SOF/RBV	Univariable			Multivariable
	OR	95%CI	P value	OR	95%CI	P value
Age, per yr	0.98	0.95-1.01	0.14
Race, black	0.33	0.13-0.80	0.02
Gender, female	1.96	1.08-3.65	0.03
BMI, per kg/m2	0.96	0.90-1.01	0.15
Diabetes	0.95	0.50-1.83	0.87
Naïve to treatment	1.24	0.71-2.19	0.45
PI failure	0.33	0.11-0.89	0.03
HCV viral load, per log IU/mL	0.80	0.56-1.11	0.2
HCV genotype
1	Ref	Ref	Ref	Ref	Ref	Ref
2	7.24	0.57-1.29	< 0.01	4.66	2.06-11.42	< 0.01
3	3.29	1.55-7.37	< 0.01	2.76	1.22-6.59	0.02
4	2.03	0.57-8.21	0.28	1.91	0.51-8.06	0.35
Hemoglobin, per g/dL	1.11	0.95-1.32	0.17
Platelet, per 103/μL	1.01	1.01-1.02	< 0.01
ALT, per U/L	1	0.99-1.00	0.1
AST, per U/L	0.99	0.99-1.00	< 0.01
Total bilirubin, per mg/dL	0.37	0.24-0.55	< 0.01	0.47	0.30-0.69	< 0.01
Albumin, per g/dL	3.15	1.98-5.19	< 0.01
FIB-4 ≥ 3.25	0.23	0.12-0.45	< 0.01

CI: Confidence interval; OR: Odds ratio; BMI: Body mass index; PI: Protease inhibitor; HCV: Hepatitis C virus; ALT: Alanine transaminase; AST: Aspartate transaminase; SOF: Sofosbuvir; RBV: Ribavirin; SVR: Sustained virological response.